Authors: Stonehouse, Anthony H.; Maggs, David G.

Source: Current Drug Therapy, Volume 2, Number 2, May 2007 , pp. 151-160(10)

Publisher: Bentham Science Publishers

Abstract:

Type 2 diabetes results from progressive β-cell dysfunction and insulin resistance, leading to progressive worsening of glycemic control, and increased risk of microvascular and macrovascular complications.

Traditionally, treatment strategies for type 2 diabetes have concentrated on compensating for insulin deficiency and reducing insulin resistance. These approaches sequentially utilize diet and exercise, oral antidiabetic drug therapy, and ultimately, exogenous insulin. However, current therapies have little effect on the inexorable decline of β-cell dysfunction, and in a group of patients already overweight or obese, treatment often comes with further weight gain. Consequently, patients often experience deterioration of glycemic control as their disease progresses while battling obesity. Several new therapies including new insulin platforms and new classes of pharmaceutical agents with unique modes of action have recently been introduced or are in clinical development for use in patients with type 2 diabetes. These include amylinomimetics, incretin mimetics, DPP-IV inhibitors, and glucagon antagonists. These new agents improve glycemia and in some instances can reduce body weight. Furthermore, anti-obesity agents, either currently available or in development, are being investigated for their potential to treat diabetes. This review focuses primarily on these new therapeutic approaches, particularly those that improve glycemic control while improving control of body weight.

Keywords: Amylinomimetic; DPP-IV inhibitor; glucagon antagonist; incretin mimetic; rimonabant; weight lowering therapies

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157488507780619103

Affiliations: 1: Amylin Pharmaceuticals, Inc., 9360 Towne Centre Dr., San Diego, CA 92121, USA.

Publication date: 2007-05-01

More about this publication?

• Current Drug Therapy publishes frontier reviews on all the latest advances in drug therapy. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: new and existing drugs, therapies and medical devices.
  
  The journal is essential reading for all researchers and clinicians involved in drug therapy.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Stonehouse, Anthony H. ;  Maggs, David G.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers